Prudential Financial Inc. Grows Position in Hologic, Inc. $HOLX

Prudential Financial Inc. grew its stake in Hologic, Inc. (NASDAQ:HOLX) by 5.2% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 129,386 shares of the medical equipment provider’s stock after buying an additional 6,431 shares during the period. Prudential Financial Inc.’s holdings in Hologic were worth $8,431,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the stock. Capital Investment Counsel Inc grew its stake in shares of Hologic by 2.6% during the 2nd quarter. Capital Investment Counsel Inc now owns 5,814 shares of the medical equipment provider’s stock valued at $379,000 after acquiring an additional 150 shares during the period. Greenleaf Trust lifted its holdings in Hologic by 5.1% during the second quarter. Greenleaf Trust now owns 3,579 shares of the medical equipment provider’s stock valued at $233,000 after purchasing an additional 173 shares in the last quarter. Savant Capital LLC boosted its position in shares of Hologic by 1.2% in the second quarter. Savant Capital LLC now owns 19,606 shares of the medical equipment provider’s stock worth $1,278,000 after purchasing an additional 232 shares during the period. First American Bank increased its stake in shares of Hologic by 0.9% in the second quarter. First American Bank now owns 28,705 shares of the medical equipment provider’s stock worth $1,870,000 after purchasing an additional 245 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. raised its position in shares of Hologic by 1.7% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 14,788 shares of the medical equipment provider’s stock valued at $964,000 after purchasing an additional 246 shares during the period. Institutional investors own 94.73% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on HOLX. Needham & Company LLC reaffirmed a “hold” rating on shares of Hologic in a report on Tuesday, November 4th. JPMorgan Chase & Co. restated a “neutral” rating and issued a $78.00 price objective on shares of Hologic in a research report on Wednesday, October 22nd. Argus increased their target price on Hologic from $80.00 to $90.00 and gave the stock a “buy” rating in a research report on Friday, September 19th. Mizuho cut Hologic from an “outperform” rating to a “neutral” rating and boosted their price target for the stock from $70.00 to $78.00 in a report on Thursday, October 23rd. Finally, Evercore ISI set a $78.00 price objective on shares of Hologic and gave the company an “outperform” rating in a report on Tuesday, October 7th. Five equities research analysts have rated the stock with a Buy rating and fifteen have given a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $79.67.

Insiders Place Their Bets

In related news, CEO Stephen P. Macmillan sold 138,358 shares of the company’s stock in a transaction on Monday, September 22nd. The shares were sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the sale, the chief executive officer owned 1,234,624 shares of the company’s stock, valued at $82,682,769.28. This represents a 10.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Christiana Stamoulis sold 7,402 shares of Hologic stock in a transaction on Monday, October 20th. The stock was sold at an average price of $73.07, for a total transaction of $540,864.14. Following the completion of the transaction, the director directly owned 47,336 shares of the company’s stock, valued at $3,458,841.52. The trade was a 13.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 1.88% of the stock is owned by corporate insiders.

Hologic Price Performance

Shares of Hologic stock opened at $74.98 on Friday. The firm has a market cap of $16.71 billion, a PE ratio of 31.11, a PEG ratio of 2.54 and a beta of 0.65. The stock has a 50 day moving average of $71.48 and a 200 day moving average of $66.96. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 12 month low of $51.90 and a 12 month high of $80.31.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Monday, November 3rd. The medical equipment provider reported $1.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.10 by $0.03. The business had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $1.03 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The company’s revenue was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.01 EPS. On average, research analysts expect that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.